Home / Stocks / MLTX

MLTX insider trading

MoonLake Immunotherapeutics — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
1
Bought · 24 mo
$99k
Buys · last 90 days
0 · $0
Most recent buy
2025-10-09

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-07-23Reich Kristian
Chief Scientific Officer
Sold50,000$20.02$1.0M
2026-07-13Santos da Silva Jorge
Chief Executive Officer
Sold68,289$20.02$1.4M
2026-04-14Santos da Silva Jorge
Chief Executive Officer
Sold98,127$18.41$1.8M
2026-04-10Bodenstedt Matthias
Chief Financial Officer
Sold85,870$18.94$1.6M
2026-04-02BIOTECHNOLOGY VALUE FUND II LP
Director · 10% owner
Sold3,750,000$16.79$63.0M
2025-12-10Santos da Silva Jorge
Chief Executive Officer
Sold200,000$14.87$3.0M
2025-12-10Reich Kristian
Chief Scientific Officer
Sold202,908$14.85$3.0M
2025-10-09Bodenstedt Matthias
Chief Financial Officer
Bought10,870$9.09$99k
2025-10-01Chen Bihua
Insider
Sold6,423,403$7.19$46.2M
2025-07-07Moukheibir Catherine
Director
Sold23,500$48.79$1.1M
2024-10-08BIOTECHNOLOGY VALUE FUND II LP
Director · 10% owner
Sold2,000,000$50.00$100.0M
2024-10-08Sturge Simon
Director
Sold171,000$53.72$9.2M

Most active insider buyers

InsiderRoleBuysTotal bought
Bodenstedt MatthiasChief Financial Officer1$99k

See MLTX on the chart

Every insider buy and sell for MLTX plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.